vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and SIMMONS FIRST NATIONAL CORP (SFNC). Click either name above to swap in a different company.
SIMMONS FIRST NATIONAL CORP is the larger business by last-quarter revenue ($197.3M vs $183.1M, roughly 1.1× Amphastar Pharmaceuticals, Inc.). On growth, SIMMONS FIRST NATIONAL CORP posted the faster year-over-year revenue change (19.6% vs -1.8%). SIMMONS FIRST NATIONAL CORP produced more free cash flow last quarter ($411.4M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 0.6%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Simmons Bank is a bank with operations in Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas. It is the primary subsidiary of Simmons First National Corporation, a bank holding company.
AMPH vs SFNC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $197.3M |
| Net Profit | $24.4M | — |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | — |
| Net Margin | 13.3% | — |
| Revenue YoY | -1.8% | 19.6% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $197.3M | ||
| Q3 25 | $191.8M | $186.7M | ||
| Q2 25 | $174.4M | $214.2M | ||
| Q1 25 | $170.5M | $209.6M | ||
| Q4 24 | $186.5M | $208.5M | ||
| Q3 24 | $191.2M | $174.8M | ||
| Q2 24 | $182.4M | $197.2M | ||
| Q1 24 | $171.8M | $195.1M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-562.8M | ||
| Q2 25 | $31.0M | $54.8M | ||
| Q1 25 | $25.3M | $32.4M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $24.7M | ||
| Q2 24 | $37.9M | $40.8M | ||
| Q1 24 | $43.2M | $38.9M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | — | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 21.9% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | — | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | 27.9% | — |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -301.5% | ||
| Q2 25 | 17.8% | 25.6% | ||
| Q1 25 | 14.8% | 15.5% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 14.1% | ||
| Q2 24 | 20.8% | 20.7% | ||
| Q1 24 | 25.1% | 19.9% |
| Q4 25 | $0.51 | $0.36 | ||
| Q3 25 | $0.37 | $-4.00 | ||
| Q2 25 | $0.64 | $0.43 | ||
| Q1 25 | $0.51 | $0.26 | ||
| Q4 24 | $0.74 | $0.38 | ||
| Q3 24 | $0.78 | $0.20 | ||
| Q2 24 | $0.73 | $0.32 | ||
| Q1 24 | $0.81 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | $620.0M |
| Stockholders' EquityBook value | $788.8M | $3.4B |
| Total Assets | $1.6B | $24.5B |
| Debt / EquityLower = less leverage | 0.77× | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | $620.0M | ||
| Q3 25 | $608.6M | $667.8M | ||
| Q2 25 | $607.7M | $1.0B | ||
| Q1 25 | $603.9M | $1.3B | ||
| Q4 24 | $601.6M | $1.1B | ||
| Q3 24 | $596.4M | $1.4B | ||
| Q2 24 | $586.9M | $1.7B | ||
| Q1 24 | $594.0M | $1.2B |
| Q4 25 | $788.8M | $3.4B | ||
| Q3 25 | $776.7M | $3.4B | ||
| Q2 25 | $757.5M | $3.5B | ||
| Q1 25 | $751.3M | $3.5B | ||
| Q4 24 | $732.3M | $3.5B | ||
| Q3 24 | $727.7M | $3.5B | ||
| Q2 24 | $713.3M | $3.5B | ||
| Q1 24 | $672.4M | $3.4B |
| Q4 25 | $1.6B | $24.5B | ||
| Q3 25 | $1.7B | $24.2B | ||
| Q2 25 | $1.6B | $26.7B | ||
| Q1 25 | $1.6B | $26.8B | ||
| Q4 24 | $1.6B | $26.9B | ||
| Q3 24 | $1.5B | $27.3B | ||
| Q2 24 | $1.5B | $27.4B | ||
| Q1 24 | $1.6B | $27.4B |
| Q4 25 | 0.77× | 0.18× | ||
| Q3 25 | 0.78× | 0.20× | ||
| Q2 25 | 0.80× | 0.28× | ||
| Q1 25 | 0.80× | 0.35× | ||
| Q4 24 | 0.82× | 0.32× | ||
| Q3 24 | 0.82× | 0.40× | ||
| Q2 24 | 0.82× | 0.50× | ||
| Q1 24 | 0.88× | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $449.5M |
| Free Cash FlowOCF − Capex | $24.6M | $411.4M |
| FCF MarginFCF / Revenue | 13.4% | 208.5% |
| Capex IntensityCapex / Revenue | 4.5% | 19.3% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $717.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $449.5M | ||
| Q3 25 | $52.6M | $223.4M | ||
| Q2 25 | $35.6M | $77.6M | ||
| Q1 25 | $35.1M | $32.8M | ||
| Q4 24 | $29.0M | $425.9M | ||
| Q3 24 | $60.0M | $199.4M | ||
| Q2 24 | $69.1M | $86.1M | ||
| Q1 24 | $55.3M | $57.6M |
| Q4 25 | $24.6M | $411.4M | ||
| Q3 25 | $47.2M | $216.7M | ||
| Q2 25 | $25.0M | $66.3M | ||
| Q1 25 | $24.4M | $22.6M | ||
| Q4 24 | $16.6M | $380.4M | ||
| Q3 24 | $46.2M | $187.7M | ||
| Q2 24 | $63.1M | $72.7M | ||
| Q1 24 | $46.5M | $47.7M |
| Q4 25 | 13.4% | 208.5% | ||
| Q3 25 | 24.6% | 116.1% | ||
| Q2 25 | 14.3% | 31.0% | ||
| Q1 25 | 14.3% | 10.8% | ||
| Q4 24 | 8.9% | 182.5% | ||
| Q3 24 | 24.1% | 107.4% | ||
| Q2 24 | 34.6% | 36.9% | ||
| Q1 24 | 27.1% | 24.5% |
| Q4 25 | 4.5% | 19.3% | ||
| Q3 25 | 2.8% | 3.6% | ||
| Q2 25 | 6.1% | 5.3% | ||
| Q1 25 | 6.3% | 4.8% | ||
| Q4 24 | 6.7% | 21.8% | ||
| Q3 24 | 7.2% | 6.7% | ||
| Q2 24 | 3.3% | 6.8% | ||
| Q1 24 | 5.1% | 5.0% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 1.42× | ||
| Q1 25 | 1.39× | 1.01× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 8.06× | ||
| Q2 24 | 1.82× | 2.11× | ||
| Q1 24 | 1.28× | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SFNC
Segment breakdown not available.
